Posted by Michael Wonder on 16 Jan 2016

CADTH calls for patient input on a new submission from AstraZeneca for Brilinta

CADTH

15 January 2016 - CADTH has received notice of a pending submission from AstraZeneca for ticagrelor (Brilinta) for the prevention of atherothrombotic events with history of myocardial infarction.

For more details, go to: https://www.cadth.ca/ticagrelor-13

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Health technology assessment , Canada , Submission